Market News
Latest news from Stock markets.
Trump ‘Inclined' to Keep Exxon Out of Venezuela
The president said he didn't like comments from the company's CEO during a meeting Friday at the White House.
...keep reeding on wsj.com
Dell Is Approaching Bargain Territory
Dell Technologies remains a clear AI beneficiary, with robust AI server demand driving strong order and backlog growth. Despite ISG margin pressures and some commoditization risk, Q4 guidance implies a major acceleration in both revenue and AI server shipments. PC business faces a mixed outlook due to rising memory costs, but new product launches may offset sales headwinds.
...keep reeding on seekingalpha.com
My Top 5 Predictions for Nvidia in 2026
Nvidia has built an AI chip empire, and that's resulted in explosive revenue growth in recent years. The stock price has followed, soaring more than 1,000% over three years.
...keep reeding on fool.com
Apple Has What It Takes To Keep Growing Through 2030
Apple is projected to deliver ~12% annual share price appreciation through 2030, driven by robust hardware and services growth. Custom silicon integration, new product launches (iPhone Fold, AR glasses), and home automation/security are key catalysts supporting AAPL's premium positioning and revenue growth. Services revenue, while below previous forecasts, continues to grow at a double-digit CAGR, with ecosystem expansion fueling high-margin incremental revenue.
...keep reeding on seekingalpha.com
Trump says he might keep Exxon out of Venezuela
U.S. President Donald Trump said on Sunday that he might block Exxon Mobil from investing in Venezuela after the oil major's CEO called the country "uninvestable" during a White House meeting last week.
...keep reeding on reuters.com
Faraday Future Founder and Co-CEO YT Jia Shares Weekly Investor Update: Announces Faraday Future's Outlook for 2026
LOS ANGELES, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) (“Faraday Future”, “FF” or the “Company”), a California-based global shared intelligent electric mobility ecosystem company, today shared a weekly business update from YT Jia, Founder and Global Co-CEO of FF.
...keep reeding on globenewswire.com
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Varonis Systems
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Varonis To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Varonis between February 4, 2025 and October 28, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - January 11, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Varonis Systems, Inc. ("Varonis" or the "Company") (NASDAQ: VRNS) and reminds investors of the March 9, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
...keep reeding on newsfilecorp.com
IWY vs. VUG: How Fees and Diversification Set These Popular Growth ETFs Apart
IWY charges a higher expense ratio than VUG. VUG holds more stocks and manages significantly larger assets under management.
...keep reeding on fool.com
Oil climbs, intensifying unrest in Iran spark supply concerns
Oil prices extended gains on Monday on growing concerns that intensifying protests in Iran could disrupt supply from the OPEC producer although efforts to quickly resume oil exports from Venezuela are limiting price gains.
...keep reeding on reuters.com
Argo Biopharma to Present at the 44th Annual J.P. Morgan Healthcare Conference
/PRNewswire/ -- Argo Biopharmaceutical Co., Ltd. (Argo Biopharma), a clinical-stage biotechnology company committed to developing next-generation siRNA
...keep reeding on prnewswire.com
Alamar Biosciences annonce la clôture d'un financement par billets convertibles sursouscrits et l'élargissement de l'équipe de direction
/PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), un leader de la protéomique de précision qui se consacre à la détection précoce des maladies, a annoncé la
...keep reeding on prnewswire.com
Gold Rises Amid Geopolitical Risks
Gold rose in the early Asian session. Rising geopolitical risks linked to Iran and Venezuela have revived safe-haven demand for gold, Saxo Bank said.
...keep reeding on wsj.com
SNCY Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Sun Country Airlines Holdings, Inc. is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Sun Country Airlines Holdings, Inc. (NASDAQ: SNCY) to Allegiant Travel Company for 0.1557 shares of Allegiant common stock and $4.10 in cash for each Sun Country share is fair to Sun Country shareholders. Halper Sadeh encourages Sun Country shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@.
...keep reeding on businesswire.com
Oil Rises Amid Middle East Tensions
Oil rose in the early Asian session amid Middle East tensions that could lead to supply disruptions.
...keep reeding on wsj.com
ALGT Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of Allegiant Travel Company is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Allegiant Travel Company (NASDAQ: ALGT) and Sun Country Airlines is fair to Allegiant shareholders. Upon completion of the proposed transaction, Allegiant shareholders will own approximately 67% of the combined company. Halper Sadeh encourages Allegiant shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763.
...keep reeding on businesswire.com
Natural Gas News: Weekly Chart Analysis Points to Further Losses on Warm Weather
Natural gas market faces continued pressure from warm weather and record production. Chart analysis suggests sellers remain firmly in control.
...keep reeding on fxempire.com
2 Reasons to Buy Amazon Stock in 2026
The generative AI megatrend is getting long in the tooth. But Amazon's diversification gives it a layer of safety.
...keep reeding on fool.com
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of StubHub
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In StubHub To Contact Him Directly To Discuss Their Options If you purchased or otherwise acquired stock of StubHub pursuant and/or traceable to StubHub's registration statement for the initial public offering held on or about September 17, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - January 11, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against StubHub Holdings, Inc. ("StubHub" or the "Company") (NYSE: STUB) and reminds investors of the January 23, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
...keep reeding on newsfilecorp.com
Why StubHub Stock Popped by 15% Last Month
Before December, it wasn't a popular stock immediately following its September IPO. It announced several partnerships as 2025 came to a close, and a tie-up with a prominent AI developer.
...keep reeding on fool.com
Why Investors Froze out Lennar Stock in December
Many investors were down on homebuilder stocks generally that month. This wasn't helped by Lennar's fourth-quarter earnings miss.
...keep reeding on fool.com
What This Insider Trim at AnaptysBio Means for Investors After a 260% Stock Rally
An AnaptysBio director sold 3,900 shares of the stock on Dec. 23 for a total value of $193,342.50. The sale represented 28.82% of J.
...keep reeding on fool.com
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Stride
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Stride To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Stride between October 22, 2024 and October 28, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - January 11, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Stride, Inc. ("Stride" or the "Company") (NYSE: LRN) and reminds investors of the January 12, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
...keep reeding on newsfilecorp.com
It's Official: Warren Buffett Has Retired. But Here Are 3 Ways to Continue Benefiting From His Investing Wisdom in 2026.
Buffett handed over the Berkshire Hathaway CEO position to Greg Abel at the start of this year. The investing legend led Berkshire to market-beating performance over many decades.
...keep reeding on fool.com
Allegiant to acquire Sun Country Airlines for $1.5B
The deal will expand the combined company's network, adding more destinations across the US and international markets.
...keep reeding on nypost.com
SCHG vs. MGK: Are Investors Better Off With Diversified Tech Exposure or a Mega-Cap ETF?
SCHG costs less to own than MGK, with a lower expense ratio. MGK has outperformed over the past year, but both funds show similar long-term risk and drawdown profiles.
...keep reeding on fool.com
Walmart's OnePay Employee Share Repurchase Hints at $4 Billion Valuation
Walmart-backed FinTech OnePay is now reportedly a $4 billion company. OnePay reached that valuation, up from $2.5 billion in 2024, after repurchasing shares from employees, Bloomberg News reported Friday (Jan. 9), citing a source familiar with the matter.
...keep reeding on pymnts.com
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sprouts Farmers Market
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in Sprouts to Contact Him Directly to Discuss Their Options If you purchased or acquired securities in Sprouts between June 4, 2025 and October 29, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - January 11, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Sprouts Farmers Market, Inc. ("Sprouts" or the "Company") (NASDAQ: SFM) and reminds investors of the January 26, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
...keep reeding on newsfilecorp.com
VARON Introduces VP-8 Lite: Portable, Reliable Oxygen Support to Start 2026
/PRNewswire/ -- As 2026 begins, many people are setting goals to live healthier, stay active, and take control of their well-being. For those who rely on
...keep reeding on prnewswire.com
Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation
Richard Francis, Teva's President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 8:15 A.M. Pacific Time (11:15 A.M. Eastern Time) Richard Francis, Teva's President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 8:15 A.M. Pacific Time (11:15 A.M. Eastern Time)
...keep reeding on globenewswire.com
Esperion Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
– Reports $156 to $160 Million in Preliminary* Full-Year 2025 U.S. Net Product Sales, a 35% to 38% Increase Compared With Full-Year 2024 –
...keep reeding on globenewswire.com
Zymeworks Outlines Strategic Priorities and Outlook for 2026
VANCOUVER, British Columbia, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today outlined its strategic priorities and key milestones for 2026. Following a year of significant clinical, operational and financial progress, Zymeworks is focused on executing a long-term strategy designed to maximize value creation for patients, partners, and shareholders.
...keep reeding on globenewswire.com
Java World Mag Provides Follow-Up Context on Previously Reported Brian Ferdinand's Protective Federal Filing
Las Vegas, NV, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Java World Mag is issuing this follow-up report to provide additional factual and legal context regarding its previously published investigative article concerning a protective federal filing initiated by Brian Ferdinand. As previously reported, the filing was made under the United States Bankruptcy Code for the limited purpose of preserving access, if required, to the statutory limitations set forth in Section 502(b)(6)-the sole federal provision governing caps on commercial lease termination and rejection claims.
...keep reeding on globenewswire.com
If You'd Invested $100 in Nvidia 10 Years Ago, Here's How Much You'd Have Today
Nvidia has been the stock market's biggest success story over the last decade. The company's dominance in AI hardware has translated into incredible gains for patient shareholders.
...keep reeding on fool.com
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of SLM Corporation
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in SLM to Contact Him Directly to Discuss Their Options If you purchased or acquired securities in SLM between July 25, 2025 and August 14, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - January 11, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against SLM Corporation ("SLM" or the "Company") (NASDAQ: SLM) and reminds investors of the February 17, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
...keep reeding on newsfilecorp.com
Tempus Achieves Record Total Contract Value Exceeding $1.1 Billion
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a record Total Contract Value (TCV) of >$1.1 billion as of December 31, 2025. During 2025, Tempus signed data agreements with over 70 customers, spanning both large and mid-sized pharma, including AstraZeneca, GlaxoSmithKline, Bristol Myers Squibb, Pfizer, Novartis, Merck, Abbvie, Daiichi Sankyo, Eli Lilly, Boehringer Ingelheim, and biotechs.
...keep reeding on businesswire.com
SoundHound AI: Buy or Sell in 2026?
SoundHound AI's business is growing, but the stock price is down 38% in the last year. Management indicated that the company is working to lower losses in the upcoming quarter and move toward profitability.
...keep reeding on fool.com
StubHub Deadline: STUB Investors Have Opportunity to Lead StubHub Holdings, Inc. Securities Lawsuit
NEW YORK, Jan. 11, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of StubHub Holdings, Inc. (NYSE: STUB) pursuant and/or traceable to the Registration Statement issued in connection with StubHub's September 2025 initial public offering (the "IPO"), of the important January 23, 2026 lead plaintiff deadline. So what: If you purchased StubHub common stock you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
...keep reeding on prnewswire.com
Hyun Woo Kim, President and CEO of the Seoul Business Agency: "The Global Innovation Forum, bringing together startup ecosystem leaders from seven countries, will mark a milestone in innovation and growth through startup exchange"
/PRNewswire/ -- Seoul Business Agency (SBA) announced the successful conclusion of the Global Innovation Forum, a global startup ecosystem networking event
...keep reeding on prnewswire.com
Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo
NEW YORK and PARSIPPANY, N.J., Jan. 11, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced a funding agreement of up to $500 million to accelerate the clinical development of Teva's anti-IL-15 antibody, TEV-'408. IL-15 is a key cytokine involved in multiple immune-mediated disease pathways. Emerging Phase 1b data from the ongoing TEV-‘408 vitiligo study provides preliminary support for IL-15 as a potential therapeutic target to treat a broad variety of autoimmune conditions. Teva anticipates sharing results from TEV-‘408 trials during 2026.
...keep reeding on globenewswire.com
Allegiant to buy rival budget airline Sun Country for around $1.5 billion
Budget air carriers Allegiant and Sun Country Airlines will merge, the companies said Sunday, the latest move toward consolidation in a heavily competitive industry.
...keep reeding on marketwatch.com
3 REITs Every Investor Should Know About
Although they've underperformed of late, real estate investment trusts are still worth a closer look. The recent rise of interest rates following a prolonged period of below-average levels could help restore REITs' long-term performance.
...keep reeding on fool.com
Day One Announces Preliminary 2025 OJEMDA™ Net Product Revenue And Provides 2026 Net Product Revenue Guidance
Preliminary 2025 net product revenue of $155.4 million, representing 172% year-over-year growth; OJEMDA 2026 U.S. net product revenue projected to be $225 - $250 million Company to present on corporate progress and priorities for 2026 during J.P. Morgan Healthcare Conference, January 12th at 5:15 pm PT (8:15 pm ET) BRISBANE, Calif.
...keep reeding on globenewswire.com
Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo
PARSIPPANY, N.J., and NEW YORK, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Royalty Pharma plc (Nasdaq: RPRX), today announced a funding agreement of up to $500 million to accelerate the clinical development of Teva's anti-IL-15 antibody, TEV-'408. IL-15 is a key cytokine involved in multiple immune-mediated disease pathways. Emerging Phase 1b data from the ongoing TEV-‘408 vitiligo study provides preliminary support for IL-15 as a potential therapeutic target to treat a broad variety of autoimmune conditions. Teva anticipates sharing results from TEV-‘408 trials during 2026.
...keep reeding on globenewswire.com
Kura Oncology Highlights Recent Accomplishments, Preliminary KOMZIFTI Revenue and Anticipated 2026 Milestones
– Launched KOMZIFTI ™ (ziftomenib), first and only once-daily, oral menin inhibitor approved for adults with R/R NPM1-mutated AML – – $2.1 million KOMZIFTI net product revenue for the period from first commercial sale on November 21, 2025, through December 31, 2025 – – Company poised for breakthrough progress in 2026 with deep pipeline of potentially transformative therapies – SAN DIEGO, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today highlighted recent accomplishments, reported preliminary KOMZIFTI™ (ziftomenib) net product revenue and outlined anticipated 2026 milestones. “Following the landmark FDA approval of KOMZIFTI on November 13, 2025, we are executing a robust commercial launch to drive rapid adoption and market share growth,” said Troy Wilson, Ph.D.
...keep reeding on globenewswire.com
Tempus Announces Preliminary Fourth Quarter and Full Year 2025 Results
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced select, preliminary, unaudited results for the fourth quarter and full year ended December 31, 2025. Full Year 2025 Select, Preliminary, Unaudited Financial Results Revenue of ~$1.27 billion, representing ~83% growth year-over-year, including ~30% organic growth (excluding Ambry) Diagnostics revenue of ~$955 million, representing ~111% growth ye.
...keep reeding on businesswire.com
Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial Transition
Alignment Reached with U.S. FDA on Potential Accelerated Approval Pathway for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) Based on Biomarker Endpoints U.S. B iologics Licensing Application (BLA) Submission for risto-cel (Previously Known as BEAM-101) Expected as Early as Year-End 2026 Expansion of Liver-targeted Genetic Disease Franchise Underway with New Program to be Announced in First Half of 2026 Ended 2025 with Estimated $1.25 Billion in Cash, Cash Equivalents and Marketable Securities; Projected Operating Runway Extension into 2029 Supports Anticipated risto-cel Launch and Execution of BEAM-302 Pivotal Development Plan CAMBRIDGE, Mass., Jan. 11, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM) today announced continued progress toward its mission to build a sustainable, predictable model for the advancement of precision genetic medicines, highlighting recent updates for its liver-targeted genetic disease and hematology franchises and strategic priorities in 2026, supported by an extended anticipated operating runway.
...keep reeding on globenewswire.com
Guardant Health Announces Preliminary Fourth Quarter and Full Year 2025 Results
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced preliminary, unaudited results for the quarter and full year ended December 31, 2025. Fourth quarter 2025 preliminary unaudited financial results For the three-month period ended December 31, 2025, as compared to the same period of 2024: Total revenue of approximately $280 million, an increase of 39% Reported approximately 79,000 oncology tests, an increase of 38% Report.
...keep reeding on businesswire.com
Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced business and program updates ahead of upcoming investor meetings in January, including the company's scheduled webcast from the 44th annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 5:15 p.m. ET/2:15 p.m. PT. “2025 was a year of strong commercial execution and rapid R&D progress, setting up the company for continued growth and many important milestones in 2026,” said Reshma Ke.
...keep reeding on businesswire.com
Alnylam Launches “Alnylam 2030” Strategy to Drive Next Era of Growth and Patient Impact
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced its new five-year strategy, “Alnylam 2030,” focused on scaling the Company's operations through achieving leadership in ATTR amyloidosis, driving long-term growth through sustainable innovation, and delivering exceptional financial results with discipline and agility. Alnylam also today reported preliminary* fourth quarter and full year 2025 global net product.
...keep reeding on businesswire.com
HealthEx Partners with Anthropic to Turn Patients’ Scattered Medical Records into Actionable Health Insights
SAN FRANCISCO, Jan. 11, 2026 (GLOBE NEWSWIRE) -- JP Morgan Healthcare Conference - HealthEx today announced its partnership with Anthropic to securely connect personal health records to Claude. Available now, Claude Pro and Max users can link their comprehensive medical history across multiple providers to Claude and receive health insights based on their records through natural language conversations, marking one of Anthropic's first consumer health integrations.
...keep reeding on globenewswire.com
La batterie du magazine GAC et la batterie à l'état solide remportent une grande distinction nationale
/PRNewswire/ -- Le 29 décembre, la conférence « Forging the Path to National Strength: Les réalisations manufacturières de la Chine dans le cadre du 14e plan
...keep reeding on prnewswire.com